Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Association between CYP2C19 genotype and proguanil oxidative polymorphism

J K Coller1, A A Somogyi, F Bochner

  • 1Department of Clinical and Experimental Pharmacology, University of Adelaide, Australia.

British Journal of Clinical Pharmacology
|June 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Factors associated with persistent opioid use 6-12 months after primary total knee arthroplasty.

Anaesthesia·2022
Same author

Amitriptyline prevents CPT-11-induced early-onset diarrhea and colonic apoptosis without reducing overall gastrointestinal damage in a rat model of mucositis.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2018
Same author

Persistent postoperative pain after total knee arthroplasty: a prospective cohort study of potential risk factors.

British journal of anaesthesia·2018
Same author

Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression.

Acta psychiatrica Scandinavica·2016
Same author

Pharmacogenetics of opioid response.

Clinical pharmacology and therapeutics·2015
Same author

Opioid activation of toll-like receptor 4 contributes to drug reinforcement.

The Journal of neuroscience : the official journal of the Society for Neuroscience·2012
Same journal

N-acetylcysteine for non-paracetamol-induced acute liver failure in children: A systematic review and meta-analysis.

British journal of clinical pharmacology·2026
Same journal

Anti-seizure medications and DRESS in paediatric patients: A FAERS disproportionality and time-to-onset analysis.

British journal of clinical pharmacology·2026
Same journal

Modelling immune gene expression profiles as pharmacodynamic endpoints of antileishmanial treatment.

British journal of clinical pharmacology·2026
Same journal

The effect of mild and moderate hepatic impairment on the pharmacokinetics, safety and tolerability of balcinrenone.

British journal of clinical pharmacology·2026
Same journal

Relationship between continuous infusion meropenem PK/PD target attainment and C-reactive protein dynamics in onco-haematologic patients with febrile neutropenia.

British journal of clinical pharmacology·2026
Same journal

UGT1A1 genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).

British journal of clinical pharmacology·2026
See all related articles

Proguanil metabolism correlates with CYP2C19 genetic variations. This study suggests proguanil can be a probe for CYP2C19 polymorphism, though further research is needed to define optimal metabolic ratio thresholds.

Area of Science:

  • Pharmacogenomics
  • Drug Metabolism
  • Cytochrome P450 Enzymes

Background:

  • CYP2C19 is a key enzyme in drug metabolism.
  • Genetic variations in CYP2C19 influence drug efficacy and safety.
  • Understanding these variations is crucial for personalized medicine.

Purpose of the Study:

  • To investigate the relationship between proguanil metabolism and CYP2C19 genotype.
  • To evaluate proguanil as a potential phenotyping probe for CYP2C19 genetic polymorphism.

Main Methods:

  • Analysis of partial clearance and urinary metabolic ratio data from 10 subjects.
  • Determination of CYP2C19 genotypes using PCR amplification and restriction endonuclease digestion.

Main Results:

Related Experiment Videos

  • Proguanil's intrinsic partial clearance (PG to CG) showed a direct correlation with the number of functional CYP2C19 alleles.
  • Genotypic poor metabolizers (PMs) exhibited metabolic ratios greater than 13, while heterozygote extensive metabolizers (EMs) had ratios less than 9.

Conclusions:

  • Proguanil demonstrates potential as a phenotyping agent for CYP2C19 genetic variations.
  • Further studies are required to establish precise urinary metabolic ratio cut-offs for distinguishing between poor and extensive metabolizers.